This study was conducted in Zambia to examine health outcomes and cost impacts of the shift from 2010 option A to WHO 2013 recommendation for prevention of mother to child transmission of HIV. A decision analytic model was developed based on the national health system perspective and estimated risk and number of cases of HIV [read more …]
Publications for Option B Plus
This study estimated the additional costs and effectiveness of Option B+ through a deterministic model to simulate births, breastfeeding, and HIV infection in women in four countries, Kenya, Zambia, South Africa, and Vietnam. Findings showed that Option B+ was the most cost-effective strategy costing between $6000 and $23 000 per infection averted compared with Option A. [read more …]
Women’s Preferences Regarding Infant or Maternal Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission of HIV during Breastfeeding and Their Views on Option B+ in Dar es Salaam, Tanzania.
A qualitative study was conducted in Dar es Salaam, Tanzania to explore women’s preferences for Option A versus B for PMTCT and their views on Option B+. Focused group discussions were conducted with 27 pregnant women with unknown HIV status and 31 HIV-infected pregnant and postpartum women. Findings showed that most participant preferred Option B [read more …]
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
This study was conducted among a cohort of HIV infected pregnant women from the DREAM Center in Nairobi, Kenya. The study was to evaluate the effectiveness of Highly Active Antiretroviral Therapy (HAART) in prevention of mother to child transmission of HIV (PMTCT). It was found that the mean absolute CD4 cell count in mothers after [read more …]